{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:59:39Z","timestamp":1790949579574,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T00:00:00Z","timestamp":1653350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Aim:<\/jats:bold> Evidence on the efficacy of combination treatment of teriparatide and denosumab for osteoporosis remains controversial. We aim to compare the efficacy between the combination treatment and monotherapy among patients with postmenopausal osteoporosis.<\/jats:p><jats:p><jats:bold>Methods and results:<\/jats:bold> We systematically searched PubMed, EMBASE, the Cochrane Library, and Web of Science up to 26 January 2022, for relevant studies. This meta-analysis reviewed all randomized controlled trials (RCTs) that reported on the combination treatment of teriparatide and denosumab in patients with postmenopausal osteoporosis. The articles were examined individually by two reviewers, and the relevant data was extracted. We combined weighted mean difference (WMD) for bone mineral density (BMD) using random- or fixed- effect models and conducted subgroup analyses. Sensitivity analyses were performed, and possible publication bias was also assessed. Overall, combination treatment enhanced the mean percent change of bone mineral density in lumbar spine than monotherapy (WMD = 2.91, 95%CI: 1.983.83; <jats:italic>p<\/jats:italic> = 0.00). And, combination treatment has been beneficial for enhancing the mean percent change of BMD in hip (WMD = 3.19, 95%CI: 2.25\u223c4.13; <jats:italic>p<\/jats:italic> = 0.00). There was no significant difference between combination treatment and monotherapy in terms of the adverse events (RR = 0.81, 95%CI: 0.45\u223c1.45; <jats:italic>p<\/jats:italic> = 0.472).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The meta-analysis indicates that combination treatment led to greater BMD at the lumbar spine and hip in comparison to monotherapy, without an increased incidence of adverse events.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold> (<jats:ext-link>https:\/\/inplasy.com\/<\/jats:ext-link>), identifier (Inplasy Protocol 2734).<\/jats:p>","DOI":"10.3389\/fphar.2022.888208","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T05:40:25Z","timestamp":1653370825000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangbi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjiang","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiecheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev-med-070313-022841","article-title":"Management of Postmenopausal Osteoporosis","volume":"66","author":"Andreopoulou","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical Practice. Postmenopausal Osteoporosis","volume":"374","author":"Black","year":"","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical Practice. Postmenopausal Osteoporosis","volume":"374","author":"Black","year":"","journal-title":"N. Engl. J. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1002\/jbmr.1968","article-title":"Compound Risk of High Mortality Following Osteoporotic Fracture and Refracture in Elderly Women and Men","volume":"28","author":"Bliuc","year":"2013","journal-title":"J. Bone Miner Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and Economic burden of Osteoporosis-Related Fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J. Bone Miner Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1359\/jbmr.060802","article-title":"Change in Lumbar Spine BMD and Vertebral Fracture Risk Reduction in Teriparatide-Treated Postmenopausal Women with Osteoporosis","volume":"21","author":"Chen","year":"2006","journal-title":"J. Bone Miner Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J. Bone Miner Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1210\/jc.2012-1262","article-title":"Skeletal Histomorphometry in Subjects on Teriparatide or Zoledronic Acid Therapy (SHOTZ) Study: a Randomized Controlled Trial","volume":"97","author":"Dempster","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 Is a Master Regulator of Joint Remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.0006-341x.2000.00455.x","article-title":"Trim and Fill: A Simple Funnel-Plot-Based Method of Testing and Adjusting for Publication Bias in Meta-Analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1210\/jc.2009-1703","article-title":"Effects of Teriparatide, Alendronate, or Both in Women with Postmenopausal Osteoporosis","volume":"95","author":"Finkelstein","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/jbmr.1681","article-title":"Sclerostin and DKK1 in Postmenopausal Osteoporosis Treated with Denosumab","volume":"27","author":"Gatti","year":"2012","journal-title":"J. Bone Miner Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","article-title":"Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast Differentiation","volume":"8","author":"Glass","year":"2005","journal-title":"Dev. Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s00198-016-3647-y","article-title":"Teriparatide and Denosumab Combination Therapy and Skeletal Metabolism","volume":"27","author":"Idolazzi","year":"2016","journal-title":"Osteoporos. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2017.21640","article-title":"Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"319","author":"Kahwati","year":"2018","journal-title":"Jama"},{"key":"B20","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/s2213-8587(17)30188-2","article-title":"Osteoporosis Treatment: Recent Developments and Ongoing Challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.1210\/endo.142.10.8437","article-title":"OPG and PTH-(1-34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats","volume":"142","author":"Kostenuik","year":"2001","journal-title":"Endocrinology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/s0140-6736(17)31613-6","article-title":"Romosozumab (Sclerostin Monoclonal Antibody) versus Teriparatide in Postmenopausal Women with Osteoporosis Transitioning from Oral Bisphosphonate Therapy: a Randomised, Open-Label, Phase 3 Trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ecl.2021.08.001","article-title":"Drug-Related Hypercalcemia","volume":"50","author":"Lecoq","year":"2021","journal-title":"Endocrinol. Metab. Clin. North. Am."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(15)61120-5","article-title":"Denosumab and Teriparatide Transitions in Postmenopausal Osteoporosis (The DATA-Switch Study): Extension of a Randomised Controlled Trial","volume":"386","author":"Leder","year":"2015","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1002\/jcb.26550","article-title":"A Network Meta-Analysis on the Short-Term Efficacy and Adverse Events of Different Anti-osteoporosis Drugs for the Treatment of Postmenopausal Osteoporosis","volume":"119","author":"Liu","year":"","journal-title":"J. Cell Biochem"},{"key":"B26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis: a Meta-Analysis of Randomized Controlled Trials","volume":"21","author":"Liu","year":"","journal-title":"Climacteric"},{"key":"B27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","article-title":"Combination Therapy with Parathyroid Hormone Analogs and Antiresorptive Agents for Osteoporosis: a Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"30","author":"Lou","year":"2019","journal-title":"Osteoporos. Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement","volume":"339","author":"Moher","year":"2009","journal-title":"Bmj"},{"key":"B29","doi-asserted-by":"publisher","first-page":"16055","DOI":"10.1038\/boneres.2016.55","article-title":"Two-year Clinical Outcome of Denosumab Treatment Alone and in Combination with Teriparatide in Japanese Treatment-Naive Postmenopausal Osteoporotic Women","volume":"5","author":"Nakamura","year":"2017","journal-title":"Bone Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1002\/jbmr.3437","article-title":"How Can We Improve Osteoporosis Care? A Systematic Review and Meta-Analysis of the Efficacy of Quality Improvement Strategies for Osteoporosis","volume":"33","author":"Nayak","year":"2018","journal-title":"J. Bone Miner Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s00198-010-1494-9","article-title":"Prevalence and Costs of Osteoporotic Patients with Subsequent Non-vertebral Fractures in the US","volume":"22","author":"Pike","year":"2011","journal-title":"Osteoporos. Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1359\/jbmr.060915","article-title":"Co-treatment of PTH with Osteoprotegerin or Alendronate Increases its Anabolic Effect on the Skeleton of Oophorectomized Mice","volume":"22","author":"Samadfam","year":"2007","journal-title":"J. Bone Miner Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11914-004-0018-y","article-title":"Postmenopausal Osteoporosis","volume":"2","author":"Selby","year":"2004","journal-title":"Curr. Osteoporos. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/14397595.2018.1524997","article-title":"Efficacy of 4-year Denosumab Treatment Alone or in Combination with Teriparatide in Japanese Postmenopausal Osteoporotic Women","volume":"29","author":"Suzuki","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/gerona\/glt105","article-title":"Death, Debility, and Destitution Following Hip Fracture","volume":"69","author":"Tajeu","year":"2014","journal-title":"J. Gerontol. A. Biol. Sci. Med. Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/s2213-8587(19)30255-4","article-title":"Combination Denosumab and High Dose Teriparatide for Postmenopausal Osteoporosis (DATA-HD): a Randomised, Controlled Phase 4 Trial","volume":"7","author":"Tsai","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/s0140-6736(13)60856-9","article-title":"Teriparatide and Denosumab, Alone or Combined, in Women with Postmenopausal Osteoporosis: the DATA Study Randomised Trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5696","DOI":"10.1002\/jcp.26465","article-title":"Paradoxical Side Effects of Bisphosphonates on the Skeleton: What Do We Know and what Can We Do?","volume":"233","author":"Vargas-Franco","year":"2018","journal-title":"J. Cell Physiol"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.888208\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T05:40:29Z","timestamp":1653370829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.888208\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":38,"alternative-id":["10.3389\/fphar.2022.888208"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.888208","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]},"article-number":"888208"}}